Fluboral controls gastro-intestinal nematodes including Ascaridia galli (adult stages), Heterakis gallinarum (adult stages) and Capillaria spp. (adult stages) in chickens and Ascaris suum (adult and L4 intestinal stages) in pigs.
Dechra says Fluboral’s formula allows it to mix in drinking water quickly and easily with five seconds of stirring.
Fluboral has a guaranteed 24-hour stability without sedimentation of the suspension after dilution in drinking water and Dechra says there is no risk of inhomogeneous mixing.
Johnny Wells West, key account manager – pig and poultry at Dechra, said: “Fluboral is a welcome addition to our Solustab range of water-soluble products, providing effortless and efficient parasite control in drinking water to enable farmers and producers to start medication quickly and cost-effectively, as and when needed.”
https://www.dechra.co.uk/products/livestock/prescription/fluboral#Fluboral.
Vetoquinol UK has launched Dolpac®, its new wormer for dogs.
Dolpac® is a broad spectrum anthelmintic for dogs containing pyrantel, oxantel and praziquantel. Individually these ingredients are effective against individual worm species and the combination of all three provides specific activities against the most common roundworm and tapeworm species.
According to the company, clinical studies carried out in accordance with internationally recognised guidelines have shown that Dolpac® provides an excellent ability to reduce parasitic infection.
“Dolpac® offers vets and their clients an easy to use worming alternative at an affordable price,” explains Mark Leddy, Vetoquinol’s Marketing Department Manager. “Our aim is to help to increase the number of dog owners worming their pets at the correct frequency, which will not only protect their dogs, but their children as well. We have introduced a number of features to help achieve this objective, there are three tablet sizes to cover all weight ranges and the tablets are flavoured and easy to give, and there are dispensing envelopes in every pack. We also provide a dosing wall chart and a client worming guide.”
For more information, contact your Vetoquinol representative or visit the Dolpac website, http://www.dolpac.co.uk/, which offers information for both vets and clients.
The RCVS Disciplinary Committee has directed that a veterinary surgeon from Berkshire be removed from the Register, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a six-day hearing that concluded yesterday, James Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury, and former lead veterinary surgeon to racehorse trainer Nicky Henderson, faced four charges of serious professional misconduct concerning his treatment of Moonlit Path, a six-year-old mare owned by The Queen.
Three of the charges related to Mr Main breaching British Horseracing Authority (BHA) rules by injecting Moonlit Path with tranexamic acid (TA) on the day she was due to race; the fourth charge related to his dishonest concealment of this treatment in his practice clinical records. Nicky Henderson had himself faced a BHA Inquiry into this case in 2009 and subsequently been sanctioned.
The Committee heard that on 18 February 2009, Mr Henderson's yard requested a veterinary surgeon attend Moonlit Path to administer an injection of Dycenene the following morning. The injection was requested as the mare was prone to exercise-induced pulmonary haemorrhage. Mr Main attended on the morning of 19 February and injected the horse with intravenous tranexamic acid. Moonlit Path raced at Huntingdon later that day, along with the eventual winner, and favourite, Ravello Bay - another horse trained by Mr Henderson. Moonlit Path finished sixth and a urine sample taken from her after the race tested positive for TA.
Of the four charges, Mr Main admitted injecting Moonlit Path with TA on the day she was due to race when he knew this breached the BHA's rule prohibiting any substance other than the horse's usual feed and water being given on race day. However, Mr Main denied knowing that, if tested, a horse would test positive for TA (thereby imposing a strict liability on the trainer); he denied administering a prohibited substance to a horse with the intention to affect that horse's racing performance; and, he denied dishonestly concealing the TA injection by omitting it from his clinical records and referring to it as a 'pre-race check'.
The Committee heard and carefully considered evidence from Mr Henderson and his employees, from BHA investigating officers and its Director of Equine Science and Welfare, from an expert equine physiologist and from Mr Main himself. In its findings, the Committee stated it was "unimpressed by Mr Henderson's evidence and surprised by his apparent lack of knowledge of the rules of racing".
Whilst the Committee accepted Mr Main believed at the time that Moonlit Path would not test positive for TA, it considered he failed to fully inform himself of the medicinal product he was using; especially so as TA does not possess a Marketing Authorisation as a veterinary medicinal product. In so doing, he did not meet his professional obligation to provide Mr Henderson with the information and advice he needed.
The Committee concluded that TA was a prohibited substance and, whilst accepting that Mr Main's concern had solely been for Moonlit Path's welfare, he had actually breached BHA rules by affecting her performance through administering such a substance.
Finally, the Committee found that Mr Main had deliberately concealed the TA injection to Moonlit Path by describing it in his notes as a 'pre-race check' - a protocol developed over several years between the practice and Mr Henderson. Such inaccurate clinical records were in breach of the RCVS Guide to Professional Conduct and led the Committee to conclude he had acted dishonestly. The Committee also found Mr Main "did not act with candour" by claiming to have administered the TA injection the day before the race. On questioning by the Legal Assessor, however, he admitted that he had known that Moonlit Path was racing the same day that he administered the injection.
Professor Sheila Crispin, chairing the Committee, said: "[We] regard it as wholly unacceptable practice that a veterinary surgeon should be party to serious breaches of rules of another regulatory body in the field of animal welfare ... and which go to the very integrity of racing.
"Whilst the findings relate to a single incident, [we] are satisfied that Mr Main's actions amounted to pre-meditated misconduct ... It is highly relevant that Mr Main held positions of responsibility within the racing industry where he was required to uphold the rules and standards of the profession," she added.
Noting Mr Main's "long and hitherto unblemished career as a highly respected equine veterinary surgeon", the Committee accepted Mr Main's evidence that the reason for the administration of tranexamic acid was solely his concern about the welfare of the horse. Nevertheless, it found his evidence was "evasive, lacking in candour and on some aspects of the case his evidence was untrue".
Professor Crispin concluded: "...proven dishonesty has been held to come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect ... Having considered carefully all the mitigation put forward on Mr Main's behalf, [we] have concluded that Mr Main's behaviour was wholly unacceptable and so serious that removal of his name from the Register is required."
Ines, who graduated from the University of Santiago de Compostela in Spain in 2001, has spent the last seven years working at universities in America, Australia and Europe. She undertook her PhD in MR spectroscopy of the brain in dogs at the University of Bern-Zurich in Switzerland. She has a Masters in Radiology from University of Glasgow. She has also worked at the University of Illinois and Sydney University.
Willows clinical director Toby Gemmill said: "Ines is highly qualified and highly regarded, so is a very welcome addition to our talented imaging team. Her experience of working around the world will also be a terrific asset to the practice."
Ines said: "I am very happy and honoured to be joining Willows and to now be part of such a great diagnostic imaging team. "This is a well-known centre of excellence and I’m really looking forward to helping deliver the first class care and treatment that Willows always aims to provide."
For more information, visit www.willows.uk.net.
Vouchers for twelve months' free access to Improve's Online Bitesize CPD series will be offered to veterinary surgeons, nurses and practice managers by their Protexin Territory Manager, based on their use of products in the Protexin range.
Online Bitesize CPD offers veterinary professionals the opportunity to meet their annual CPD requirements in short bursts of learning at a time and place to suit them. Its online modules of 20, 40 and 60 minutes cover a range of clinical topics, including cardiology, ophthalmology, small animal medicine, feline medicine and exotics.
Improve says the modules have been designed to be visually engaging, highly interactive and informative to ensure that the experience is rewarding.
James Kyffin, Veterinary Director at Protexin, said: "We are thrilled to be continuing our relationship with Improve International by offering practices access to its Online Bitesize CPD. We are passionate about education and Bitesize offers a convenient, exciting way for the profession to gain access to high quality CPD."
John Douglass at Improve International added: “We hope that veterinary professionals who have not yet experienced our training will take up the opportunity created by this association with Protexin Veterinary and learn new skills with our Online Bitesize CPD service for twelve months at no cost.
"The interactive modules we have created are led by recognised experts and will help them to refresh their knowledge, learn new skills and achieve their annual CPD points quota online at any time.”
The four organisations have written a template letter which anyone can send to any company they see using brachycephalic breeds, such as the Persian, or Scottish Folds, in its marketing materials.
The letter urges companies that use images of cats to work collaboratively with veterinary professionals and pledge to avoid using such breeds in the future.
Dr Nathalie Dowgray, Head of ISFM, said: “Seeing a cute cat in an advertisement can often be a trigger for people to seek out acquiring a cat of that breed without understanding the welfare concerns associated with some pedigree breeds.
"A rise in demand can lead to an increase in breeding practices that result in severe conformational issues and poorer welfare in these breeds.
"We encourage people to download this letter to use when they see breeds of concern being used in advertising, as health is always more important than looks.”
https://icatcare.org/app/uploads/2023/09/ISFM_FECAVA_FVE_UEVPAdvert_Letter.pdf.
Ms Bucur MRCVS faced three charges against her.
The first charge was that in April 2024, she wrote a prescription for 60 tablets of tramadol 50mg, indicating that it was for the treatment of an animal, when it was intended for the treatment of a human.
The second charge was that she allowed the prescription to be presented at a pharmacy and/or failed to stop that.
The third charge was that her conduct, in relation to the first two charges was dishonest, and misleading, and took place in circumstances where she was not professionally qualified to write a prescription for human use.
At the outset of the hearing, Ms Bucur admitted all the charges and the Committee accepted her admissions.
In relation to charge three, the Committee found that Ms Bucur had been aware that she should not have written the prescription, that she should not have indicated that it was for an animal, that she should not have deleted the prescription for the clinical record on the practice management system, and she should not have allowed or failed to prevent the prescription from being presented for dispensing.
The Committee therefore found all charges proved.
In terms of aggravating factors, the Committee considered that Ms Bucur’s conduct had given rise to a risk of injury because she was not professionally qualified or sufficiently informed to issue a prescription for tramadol, that she had acted recklessly with regard to the potential effects of a controlled, potentially addictive drug and that her conduct had been premeditated.
It also accepted the submission that there was an abuse of Ms Bucur’s professional position as a registered veterinary surgeon, because this had allowed her to issue a prescription.
The Committee also found that Ms Bucur’s conduct was aggravated by her having involved other persons in her misconduct, namely her partner, in an attempt to have the prescription dispensed.
The Committee noted that the charges involved findings of dishonesty, which is regarded at the higher end in terms of the spectrum of gravity of misconduct.
In mitigation, the Committee took into account that the facts proved related to a single incident of the issuing and attempted use of a prescription.
The Committee was of the view that the Ms Bucur’s conduct had failed to promote protection of public health and had breached the legislation around access to controlled drugs.
Even though this was a single incident, the Committee considered that members of the public, if aware of the facts, would be alarmed and concerned at Ms Bucur’s actions.
As a result, the profession could be brought into disrepute and public confidence in the profession undermined.
The Committee therefore found that Ms Bucur’s conduct amounted to serious professional misconduct in a professional respect.
The Committee then considered whether there were any relevant additional personal aggravating or mitigating factors.
The Committee did not find any further aggravating factors; in mitigation it noted that Ms Bucur had no previous complaints of adverse matters in her career.
The Committee accepted that Ms Bucur had made early, open and frank admissions to her conduct.
She had also offered a fulsome and genuine apology and remorse in her witness statement and in the hearing.
The Committee also accepted that she had since worked without further incident and concluded from her witness statement and evidence that she had developed full insight into her misconduct.
She was able to provide a notable number of references and testimonials which were uniform in speaking to her positive qualities as a veterinary surgeon.
The Committee was able to conclude that this has been a very serious but single lapse of judgement, and that there was a relevant context in that Ms Bucur had clearly acted out of concerns to help her father, however misguided.
There were no suggestions of harm, or risk of harm, to animals.
However, the Committee could not ignore that Ms Bucur’s misconduct had occurred in relation to a controlled drug and had contravened important protections designed to protect the public.
Neil Slater, chairing the Committee and speaking on its behalf, said: “The Committee balanced the effect that a suspension would have on Dr Bucur, by depriving her of the ability to practise for a period, with the public interest.
"However, it decided that, in the circumstances, the interests of protecting the public, including the wider public interest, outweighed Dr Bucur’s interests.
“The Committee decided that, in all the circumstances, a suspension was the appropriate and proportionate sanction.
“The Committee considered for how long the suspension should be imposed.
"It considered that the suspension was not required to allow for Dr Bucur to gain any further insight.
"It would purely be required to mark the Committee’s disapproval of Dr Bucur’s misconduct, as a signal to the public and to the profession.
"The Committee concluded that the least period required in all the circumstances is two months.
“The Committee therefore directed to the Registrar that Dr Bucur’s registration be suspended for a period of two months.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Adrienne Conroy, Head of BSAVA Policy and Chair of the Big Issues stream said: "As a profession, we have a history of successfully dealing with the unpredictable and rising to the challenge of the unexpected, which in many ways have been the hallmarks of the past year or so and no doubt will likely continue to be so for the foreseeable future.
"This year’s Big Issues stream will look at some of the uncertainties encountered by vets in practice and how resilience and resolve in the face of challenge can continue to serve the profession well for the future."
Big Issue subjects include:
The ABC of Achievements, Brexit and ChallengesProfessor the Lord Trees will aim to support vets’ understanding of the rationale underpinning the Government's Brexit decisions and their impact on the profession. A panel of speakers will also look at how the Government and the profession has worked collaboratively to introduce legislation and policies across a range of areas affecting the companion animal sector, and the practical implications for veterinary surgeons.
Medicines: Ensuring Supply Despite CrisesProfessor Peter Borriello, CEO of the Veterinary Medicines Directorate (VMD) and Dawn Howard CEO of the National Office of Animal Health (NOAH) will explore the unpredictable challenges, whether dependent on Brexit or other factors, that can potentially threaten the supply of medicines vital to companion animal veterinary practices and how these unexpected events can be tackled and resolved by working together.
The Perils of Passports and Certification: Avoiding LitigationBSAVA President Philip Lhermette, together with Dr Mauricio Lopez, Head of Veterinary Trade Facilitation, Animal and Plant Health Agency (APHA) and Michael Stanford, Veterinary Claims Consultant, Veterinary Defence Society (VDS) will share for the first time the results of the BSAVA 2018 OV survey, and will endeavour to better equip and support vets in companion animal practice to manage the unpredictable aspects of pet passports and export certification.
Telemedicine: Patient Care in the Digital WorldDr Kate Richards, Chair of the RCVS Standards Committee, Dr Thom Jenkins, CEO of Gula, Richard Guest, CEO of telemedicine consultancy Morgan Frey and Simon Doherty, President of the BVA aim to help delegates navigate relatively the unchartered territory of telemedicine and make informed decisions on the future of telemedicine and its potential impact on not just them, but also their clients.
More information on the Big Issues agenda and speakers here.
A new book written by a man who is both married to and brother of a veterinary surgeon (not the same one, I hasten to add), offers a husband's take on a vet's life.
Author Steve Ankers is married to Margaret Ankers MRCVS (Acorn Veterinary Surgery) and brother of John Prescott MRCVS (now retired, but remains a consultant to Robson & Prescott).
His book, called It's a Dog's Life for the Other Half, is brimfull of funny anecdotes, including: holding hands with a famous actress inside a cow's rectum; a dog who ate a Cliff Richard cassette; a cat who ate a Chihuahua but spat out the tail and a vulture who travelled hundreds of miles on a car roof-rack.
Terry Jones (you know, the Python) described the book as "Hilarious and eminently readable".
It's a Dog's Life for the Other Half may be the literary equivalent of a busman's holiday for the members of this site, but I'm half way through and it's one of those rare books that's guaranteed to bring a smile to your face at least once a page.
It's a Dog's Life for the Other Half is available now from all good bookshops, including Amazon RRP £12.99. It is also available as an e-book.
MSD says the new license claim means the vaccine combines the broadest calf scour protection available with unique user convenience.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: “When correctly administered as a single 2ml intramuscular dose to pregnant cattle 12-3 weeks prior to calving, Bovilis Rotavec Corona boosts antibodies in colostrum for rotavirus, coronavirus and now both E.coli F5 (K99) and F41.
"Calves gain protection against these infectious scour pathogens by drinking the fortified colostrum from their vaccinated mothers.
“Bovilis Rotavec Corona also contains the most prevalent rotavirus strain in Europe2, which minimises the chances of a calf scour protection breakdown due to differences between vaccine antigens and the ubiquitous antigens on farm3.”
Kat added: "Vet, RAMA and farmer feedback suggests the wide vaccination window (12-3 weeks pre-calving) and the fact that an opened bottle of vaccine lasts for up to 28 days are particularly useful practical benefits in a mix of both dairy and beef suckler systems.”
Bovilis Rotavec Corona is available in 5, 20 and 50-dose packs from both veterinary professionals and the agricultural merchant trade.
References
The company says more and more CT scanners are being used in general practice, but many teams have been telling them they're not sure if they're using their scanner optimally, or that only some of the team are confident in using it.
The online training aims help teams get the best diagnostic use of CT
The first of the sessions, on 15th June, will cover the indications and benefits of CT in small animal practice.
The second on 22nd June will look at how and when to perform CT reconstructions.
Manuel Pinilla, VetCT Supporting Radiologist and Director of Quality Assurance (pictured right), will be delivering the talks.
Manuel said: “We are seeing a rapid increase in the use of CT in first opinion practice.
"We know CT can provide vital diagnostic information in addition to the more traditional modalities of x-ray and ultrasound.
"However, it can be challenging to optimise the diagnostic capability.
"We’re keen to support veterinary teams to help them get the most out of their machine and do the best for their patients and the owners.”
To register for the training, visit: https://welcome.vet-ct.com/ctcpdwebinars
Merial Animal Health has announced the launch of its new feline vaccine Purevax Rabies in the UK and Ireland.
Merial says the product offers a simple but elegant solution to rabies vaccination, without the need for adjuvant. According to the company, the non-replicative vector is processed by the cat's immune system in the same way as a live virus, triggering both a powerful cell mediated and humoral response without the need for adjuvant. However, because the vector cannot replicate effectively in mammalian cells, there is no risk of any reversion to virulence.
Merial's Veterinary Technical Manager Kevin Whelan, said: "This is a perfect complement to our existing range of advanced technology vaccines, which already offer the benefits of highly effective protection, including updated FCV strains, without the need for adjuvant. It also represents Merial's continued commitment to the development of innovative products for the animal health market".
The vaccine is licensed for use in cats from 12 weeks of age, and administration of a single injection has been shown to provide protection against disease.
Contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
Kellie Price, a Kent-based Registered Veterinary Nurse has been suspended from the Register for nine months by the RCVS RVN Disciplinary Committee after she admitted dishonestly creating four prescriptions, one of which was then fraudulently presented to a pharmacy.
The Committee heard that in January 2013, Miss Price, who did not attend the hearing and had no representation, had dishonestly created a prescription for two inhalers while working at a veterinary practice in Kent.
This prescription had been written and signed in the name of a locum veterinary surgeon, Cristiana Tudini MRCVS, without her knowledge or consent. The false prescription was subsequently presented to a pharmacy for dispensing.
In addition, in March 2013, Miss Price dishonestly created a further three prescriptions - one of which was written in the name of her colleague Cormac Higgins MRCVS, and two written in the name of Cristiana Tudini MRCVS without either's knowledge or consent. All four false prescriptions had been made out for Miss Price's Jack Russell terrier.
Upon discovering the false prescriptions, Mr Higgins asked Miss Price for an explanation and subsequently suspended her from her position pending further investigation. However, after being interviewed by Mr Higgins, she resigned before any in-house disciplinary hearing could take place. The allegations were then reported to both the RCVS and the police, the latter giving Miss Price a formal caution in respect of the false prescription made in January 2013.
In considering Miss Price's sanction, the RVN Disciplinary Committee took into account a number of aggravating and mitigating factors. In mitigation, it accepted Miss Price's explanation that, in the early hours of 6 January, she had suffered an asthma attack and that she had created the false prescription at work in a panic after realising her inhaler was empty and fearing a further asthma attack. The Committee also took into account a witness statement from Cormac Higgins MRCVS which described her as a "great nurse" and "good with patients and clients".
However, the Committee also considered aggravating factors including Miss Price's dishonesty and the fact that she then made further false prescriptions in March, although these were not then presented to a pharmacy.
Professor Noreen Burrows, who chaired the RVN Disciplinary Committee and spoke on its behalf, said: "The Committee is... satisfied that the admitted dishonesty amounts to disgraceful conduct in a professional respect [and] is satisfied that the respondent's conduct fell far short of the conduct to be expected of a registered veterinary nurse."
On deciding the sanction she added: "Taking into account all of the circumstances, the Committee has concluded that the suspension of the Respondent's name from the Register for a period of nine months is the proportionate sanction in this case."
The Committee's full findings and decision are available on the RCVS website (www.rcvs.org.uk/disciplinary).
The hour-long webinar will be held on Tuesday 18th May from 7.30pm.
Chris is a European and RCVS Recognised Specialist in Equine Dentistry and the founding Director of the Equine Dental Clinic Ltd. Nicole is a European, American and RCVS Recognised Specialist in Equine Dentistry and is a co-director of the Equine Dental Clinic.
Chris and Nicole (pictured right) will discuss key points for examination, diagnostics and treatment, including:
Zoetis Equine Product Manager, Penny McCann said: "Chris Pearce and Nicole du Toit are known worldwide for their consulting, training, educating and CPD, as well as for running the longest established and largest equine veterinary dental specialist practice in Europe.
"We are delighted that they have agreed to share their knowledge with our client practices on 18th May and look forward to welcoming you."
To book your place for the webinar, visit: https://register.gotowebinar.com/register/173596806534344203
For more information contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 8034.
The new suite offers chemotherapy and radiotherapy treatment facilities under one roof, including a linear accelerator (LINAC) which enables treatment of tumours previously considered untreatable.
Southfields has two full-time client-facing specialists in radiation oncology and two on-site, full-time double-boarded medical and radiation oncologists, along with dedicated radiotherapy technicians and therapeutic radiographers.
RCVS and European Specialist Sarah Mason, Southfield's lead in general oncology, said: “Southfields is already renowned as being the leader in cancer treatment for small animals in the UK and the opening of our dedicated oncology and radiotherapy suite takes patient care to an even higher level.”
www.southfields.co.uk
Barclaycard has launched Paywag, a new NFC payment system for dogs.
Installed in a specially designed dog collar, the new system allows dogs to make payments up to £5.00 in value in selected pet stores and veterinary practices.
Cryptisel is for use in reducing oocyst shedding in calves where diarrhoea caused by Cryptosporidium is a problem. After the presence of the causal organism has been established, Forte says Cryptisel can be used in all new-born calves to break the cycle of transmission and multiplication on-farm.
Dr John Henderson, Large Animal Product Manager with Forte Healthcare Ltd said: "Cryptisel will be a very useful medicine in the control of the most commonly-identified scour pathogen in the UK and Ireland. Used alongside the calf-rearing cornerstones of good colostrum management, hygiene, and biosecurity, Cryptisel will reduce production of Cryptosporidium oocysts and help limit spread of the disease among susceptible calves."
Cryptisel is a POM, available in 490ml and 980ml bottles. Both sizes come with a metered dosing pump for convenient administration.
For further information, contact your local Forte Territory Manager or email enquiries@fortehealthcare.com.
If you are speaking at or hosting a small animal CPD event in 2019, please email details to press@vetsurgeon.org for it to be considered for addition to this list.
This list includes events from CPD Solutions, Improve International, the Veterinary Poisons Information Service and the Small Animal Medicine Society.
Laura Padron Vega was struck off in December 2018 after dishonestly backdating two statutory Certificates of Competence submitted to the Food Standards Agency under the Welfare of Animals at the Time of Killing Regulations 2015.
She was also found to have failed in her duties as an OV because she was unprepared for, and unaware of, the new regulations and did not take adequate steps to ensure that the two people for whom she had given veterinary certification were licensed to perform slaughter in accordance with the regulations.
At the outset of the restoration hearing, Ms Padron Vega admitted her guilt and made representations that she appreciated the seriousness of her actions and that there was no chance of her repeating them. She also produced a number of testimonials, including some from former veterinary colleagues, in addition to evidence that she had endeavoured to keep up-to-date with her continuing professional development while off the Register although this had been difficult due to her financial circumstances.
In considering her application for restoration, the Committee found that Ms Padron Vega had accepted the reasons for her removal from the Register and the seriousness of the findings. It found that she was unlikely to repeat the behaviour and that her conduct had been entirely acceptable since she was removed from the Register. It also considered her financial and personal circumstances, noting the difficulty she had in securing well-paid, full-time employment since her removal from the Register, and the impact that this had on her being able to keep up-to-date with her continuing professional development.
However, the Committee expressed concerns over her efforts to keep up-to-date with the knowledge and skills she would need to return to practice and said she demonstrated “no real appreciation of what she needed to put in place to demonstrate that she can return to work safely”.
In particular it found that the CPD she had undertaken was unstructured and insufficient and that therefore she had not done enough at the present time to demonstrate that she was fit to be restored to the Register, especially as she signalled that, if restored, she hoped to work in small animal practice, an area that she had not worked in for some time.
Cerys Jones, chairing the Committee and speaking on its behalf, said: “While the Committee did not consider that the applicant was in a position to return to practice at this point, it did consider that if the applicant applies herself to a properly structured and focused Return to Practice Plan and is able to produce evidence of how she has fulfilled the requirements of that plan, then her application could prove successful within a short time.
"The outcome of the plan for a return to practice will need to ensure the continued protection of the welfare of animals as well as the interests of clients whose animals she might be called upon to treat and, most importantly, the public interest which is founded on a belief that the veterinary certification processes are beyond question or doubt."
In order to allow Ms Padron Vega sufficient time to develop this plan, the Committee adjourned the restoration hearing for seven months (until July 2021).
Ms Jones added: “This adjournment will afford [Ms Padron Vega] an early opportunity to reflect on the concerns of the Committee… and to return with a properly supported programme for the future which will show her understanding of the problems that are likely to face her on her return to practice and her proposals to meet those inevitable difficulties.”
Following the outcry from the profession over the disciplinary hearing into Mr M Chikosi, the RCVS' new Operational Board has clarified the the College's position on the use of blankets to move animals.
The hearing found Munhuwepasi Chikosi guilty of unreasonably delaying attending a dog that had been run over at a farm, and of unnecessarily causing her to remain in pain and suffering for at least an hour.
As a result, the Disciplinary Committee directed that Mr Chikosi's name be removed from the Register for serious professional misconduct. The College says that since the appeal window has closed without an appeal being made, Mr Chikosi has now been struck off.
However, the Committee also said: "... his [Mr Chikosi's] advice that Mitzi should be moved on a blanket was wrong, as she may have had an injured back."
This was widely criticised as being out of touch with the practicalities of real life and unsupported by any evidence.
Speaking on behalf of the Board, President Neil Smith said: "We fully support the decision taken by the independent Disciplinary Committee with regard to the Chikosi hearing, with one comment requiring clarification: the issue of whether a blanket can be used to move an injured dog. We consider that it is acceptable, in most cases, to transport an injured dog with the aid of a blanket.
"The profession should be reassured that our Standards Committee [the new name for Advisory Committee] will consider the general issues raised by the Chikosi hearing at its next meeting. This will not be a review of the decision, but form part of the routine consideration of DC hearings made by the Committee to see if they raise issues that require additional guidance and advice."
Phovia, which was launched in the UK last year, is a two-part FLE system consisting of a chromophore gel that is applied to the affected skin and a blue light LED lamp.
Vetoquinol says that when used together they produce light of varying wavelengths that penetrates the skin to different depths, helping to control bacteria and reduce inflammation on the surface of the skin and stimulating regeneration in the epidermal and dermal layers.
The unit is portable, and applications take four minutes once a week.
The authors of the Vetoquinol-funded study say that FLE has already been shown to support and accelerate natural skin healing, but this latest research shows that the benefits go beyond improvement in clinical signs.
The study looked at 35 dogs with a diverse range of skin conditions: 13 had interdigital furunculosis, 10 had deep pyoderma, 6 had wounds, 4 had pyotraumatic dermatitis, and 2 had perianal fistula on presentation.
Eight of 35 dogs were new cases, whereas the remaining 27 were undergoing recrudescence of a prior episode, including pyotraumatic dermatitis, wounds, deep pyoderma, interdigital furunculosis and perianal fistulae.
Thirty dogs (86%) achieved a clinical resolution: 18 with the Fluorescent Light Energy alone and 12 with the concomitant use of FLE and topical antiseptic shampoo.
Five dogs (14%) had a partial response and needed other therapies.
92% percent of owners attested to their pet’s enhanced quality of life, with 74% of dogs displaying at least a 50% improvement in owner-reported behaviour, mood, sleep and playing activities.
The study also reported a 46% reduction in caregiver burden.
Felicity Caddick, Technical Services Manager at Vetoquinol said: “Managing skin conditions often requires the long-term use of shampoos or topical therapies.
"Many owners find this aspect of pet ownership challenging, especially with larger dogs, or less cooperative animals.
"FLE can reduce or in some cases eliminate the need for topical therapies at home, not only simplifying the treatment process but also enhancing convenience and compliance.
"Sharing responsibility for administering ongoing treatment with their vet practice also removes some of the worry associated with their pet’s health.”
Vetoquinol also highlights that Phovia can offer vets a drug-free management option for skin disorders that aligns with the principles of antibiotic stewardship.
Reference
The company, which was founded by scientists from the human field, managed to raise £8 million of Series A funding by February this year. It is now seeking further investment for an extension to that Series A funding by the autumn.
The company's Chief Scientific Officer is Professor Allan Bradley, Emeritus Director of the Wellcome Trust Sanger Institute and a Fellow of the Royal Society (pictured right). He spearheaded the development of mouse transgenics and their translational use, which provided the basis for developing canine monoclonal antibody therapies.
Allan said: "We are growing a world-class scientific team that will enable PetMedix to become a global leader in the development of novel monoclonal antibody therapies for the expanding animal health market. In the short lifetime of the company we have attracted huge talent in both our scientists and executives, and moved into the heart of the Cambridge biotech sphere with its excellent facilities and networking opportunities. The recent appointment of Dr. Fabian Kausche to the board marks our intent to become a global leader in animal health."
CEO, Dr. Tom Weaver added: "We have the people and the technology in place, and are champing at the bit to progress these therapies to reach the pets that could benefit. We know this technology has transformed the treatment and survival of human patients with a variety of conditions and we want to create the same paradigm shift in veterinary treatment options to improve welfare, quality of life and longevity for our dogs and cats."
PetMedix says it is interested in hearing from potential investment partners, and mergers and acquisitions. Contact Jolyon Martin via email: jolyon.martin@PetMedix.co.uk or telephone: +44 (0) 1223 734140,
The RCVS Disciplinary Committee has suspended a Kent veterinary surgeon from the Register for eight months after he was found guilty of dishonest certification.
At the outset of the hearing held on 14/15 December, Takeshi Okano, of Lakeview Veterinary Centre in Deal, Kent, admitted charges that, whilst acting as Official Veterinarian, he had signed a number of certificates when he knew that did not have all the information needed to do so.
On 23 June 2009, Mr Okano had been asked to act as Official Veterinarian to examine four horses and sign the certificates necessary for their export to the USA. The certificates required Mr Okano to certify he had received a written declaration from the owners that the animals had been in the UK for 60 days previously. Mr Okano also signed certificates indicating that the horses had only been in France, Ireland, or the UK for the same 60-day period. Despite having received no such declarations, and having no information whatsoever of where the horses had been, Mr Okano signed the certificates. At the hearing, no explanation for Mr Okano's actions was offered.
Mrs Beverley Cottrell, Chairman of the Disciplinary Committee said: "The validity of any certificate is an integral part of the system relating to the export or import of animals. At Section G of the RCVS Guide to Professional Conduct, emphasis is given to the importance of certification, the importance of the signature and the guidance issued by DEFRA. These provisions are well known to the profession."
The Committee was satisfied that Mr Okano's actions in signing the certificates without the owners' declarations amounted to a serious departure from professional standards. In reaching a decision on sanction, it considered that, whilst a reprimand or warning would not be appropriate, neither would removing Mr Okano's name from the Register be proportionate, or necessary either in the public interest or to protect animals.
"Mr Okano is a young veterinary surgeon at the start of his career, who from the outset admitted his actions," said Mrs Cottrell noting that the testimonials from veterinary surgeons, veterinary nurses and clients, and his record of Continuing Professional Development demonstrated his commitment to high standards within the profession. "In reaching this decision, we have paid particular regard to the fact the false certification was neither persistent nor concealed, nor was he a senior veterinary surgeon."
The Committee directed Mr Okano's name be suspended from the Register for eight months.
Virbac has launched Neoprinil, an eprinomectin pour-on solution indicated for use against internal and external parasites in cattle, including gut and lungworms, mange mites, sucking and chewing lice, horn flies and warbles.
Neoprinil has a zero-day withdrawal period in milk and can be administered using the company's Farmpack and Flexibag.
The Farmpack is a backpack which holds a Flexibag of Neoprinil solution. The Flexibag is a bag designed to protect medication and preserve it once it has been opened. The two together were awarded the 2014 PharmaPack Award for Innovative Packaging.
Neoprinil offers a one year stability period once it has first been opened and requires no special conditions for storage. It is presented in 2.5L, 4.5l and 8l pack sizes.
Product Manager for Large Animals Brigitte Goasduf MRCVS said: "A high worm burden can have adverse effects on the herd's productivity and performance and so it is advisable to ensure infected animals are treated as part of a Herd Health Plan. Eprinomectin is a tried and trusted parasiticide and studies confirm that it can have a positive impact on both milk production and on weight gain. Its zero day withdrawal period is a major benefit for dairy farmers.
"With the launch first of Deltanil and, now, Neoprinil, we are reinforcing our commitment to work with veterinary surgeons and farmers to understand the everyday challenges they face and to provide practical, effective solutions. We offer a comprehensive parasiticide range with a dispensing system that sets a new standard for convenience and ease of use."
Merial Animal Health has been found in breach of the NOAH Code of Practice for literature promoting the wormer Ivomec Super.
In the literature, Merial stated that Closantel injection (Janssen Animal Health) was effective against flukes aged 9 weeks or older, when in fact, at the time the undated brochure was distributed, Closantel was effective against flukes aged 7 weeks or older.
Merial did not dispute the facts alleged: the company had relied on an out-of-date detailer. The NOAH Code of Practice Committee emphasised the need for members to ensure, when giving comparative data in promotions, that up-to-date data is used. The SPC of any authorised product can be viewed on the VMD's website.
The Committee did commend Merial Animal Health for taking corrective action within two days of notification by the Complainant.
NOAH encourages those interested in finding out more to read the full details of the Committee's rulings on the NOAH website at www.noah.co.uk/code.